Citadel Advisors’s Enliven Therapeutics ELVN Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Shares Change % | Capital Flow | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q2 | $29.5M | Buy |
1,470,424
+347,286
| +31% | +$6.97M | 0.01% | 744 |
|
|
2025
Q1 | $22.1M | Sell |
1,123,138
-615,394
| -35% | -$12.1M | ﹤0.01% | 841 |
|
|
2024
Q4 | $39.1M | Buy |
1,738,532
+4,555
| +0.3% | +$102K | 0.01% | 641 |
|
|
2024
Q3 | $44.3M | Sell |
1,733,977
-573,837
| -25% | -$14.7M | 0.01% | 530 |
|
|
2024
Q2 | $53.9M | Sell |
2,307,814
-46,589
| -2% | -$1.09M | 0.01% | 451 |
|
|
2024
Q1 | $41.4M | Sell |
2,354,403
-40,045
| -2% | -$704K | 0.01% | 566 |
|
|
2023
Q4 | $33.1M | Buy |
2,394,448
+42,957
| +2% | +$595K | 0.01% | 635 |
|
|
2023
Q3 | $32.1M | Buy |
2,351,491
+55,281
| +2% | +$755K | 0.01% | 598 |
|
|
2023
Q2 | $46.9M | Hold |
2,296,210
| – | – | 0.01% | 447 |
|
|
2023
Q1 | $50.3M | Buy |
2,296,210
+2,102,014
| +1,082% | +$46M | 0.01% | 440 |
|
|
2022
Q4 | $3.18M | Buy |
194,196
+170,360
| +715% | +$2.79M | ﹤0.01% | 2188 |
|
|
2022
Q3 | $217K | Buy |
+23,836
| New | +$217K | ﹤0.01% | 4802 |
|
|
2020
Q2 | – | Sell |
-7,942
| Closed | -$509K | – | 4789 |
|
|
2020
Q1 | $509K | Buy |
+7,942
| New | +$509K | ﹤0.01% | 3391 |
|